In this issue of Blood, Gauthier et al retrospectively analyzed the outcome of a second infusion of CD19 chimeric antigen receptor (CAR) T cells in patients with B-cell malignancies who relapsed or were refractory to the first infusion. The authors reported durable responses in a significant proportion of patients, with a low incidence of severe toxicity. They also identified actionable pretreatment factors associated with positive outcomes.
A second CD19 CAR T-cell infusion: Yes or no?
Ciceri F.
2021-01-01
Abstract
In this issue of Blood, Gauthier et al retrospectively analyzed the outcome of a second infusion of CD19 chimeric antigen receptor (CAR) T cells in patients with B-cell malignancies who relapsed or were refractory to the first infusion. The authors reported durable responses in a significant proportion of patients, with a low incidence of severe toxicity. They also identified actionable pretreatment factors associated with positive outcomes.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
